| Identification | Back Directory | [Name]
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-(dimethylamino)-ethanone | [Molecular Weight]
471.55 |
| Chemical Properties | Back Directory | [Boiling point ]
703.2±60.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [solubility ]
Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Slightly soluble: 0.1-1 mg/ml | [form ]
Solid | [pka]
8.24±0.28(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia. In vivo CHMFL-FLT3-122 significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity. | [Uses]
CHMFL-FLT3-122 is a potent, selective and orally active FLT3 kinase with an IC50 of 40 nM. CHMFL-FLT3-122 shows selectivity for FLT3 over BTK (IC50 of 421 nM) and c-KIT (IC50 of 559 nM) kinases. CHMFL-FLT3-122 induces apoptosis by arresting the cell cycle into the G0/G1 phase[1]. | [in vivo]
CHMFL-FLT3-122 (12.5-50 mg/kg; oral gavage; once a day; for 22 days) could almost completely suppress the tumor progression, and does not significantly affect the mice body weight[1]. | Animal Model: | Female nu/nu mice injected with MV4-11cells[1] | | Dosage: |
12.5 mg/kg, 25 mg/kg and 50 mg/kg | | Administration: | Oral gavage; once a day; for 22 days | | Result: | Could almost completely suppress the tumor progression. |
| [References]
[1] Xixiang Li, et al. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J Med Chem. 2015 Dec 24;58(24):9625-38. DOI:10.1021/acs.jmedchem.5b01611 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|